Technology transfer / Localization · GCC · Announced 30 Jul 2025

BioGeneric Pharma → GWM

Egypt's BioGeneric Pharma and Saudi Arabia's GWM signed a strategic partnership to localize vaccine and biologics manufacturing in the Kingdom through technology transfer and a new facility.

Parties: BioGeneric Pharma (Egypt) → GWM (Saudi Arabia)

Value
Undisclosed
Territory
Saudi Arabia
Therapeutic area
Vaccines
Asset
Vaccines and biologics (products not named)
Announced
30 Jul 2025

Our analysis

Why this matters

BioGeneric Pharma, an Egyptian biotech company, and GWM, described as a Saudi company, signed a strategic partnership, reported on 30 July 2025, to localize vaccine and biologics manufacturing in Saudi Arabia. The partnership rests on three pillars: transfer of regulated vaccine-production technology from Egypt to Saudi Arabia through a new, modern facility; direct operational entry for BioGeneric into the Saudi market; and local manufacturing under licensing or joint-venture models. Value, site, timelines and products were not disclosed.

It is a south-to-south transfer: an Egyptian biotech exporting manufacturing know-how to the Gulf, not a Western multinational. For BD directors, Egyptian biologics players are emerging as technology partners for Saudi localization, not only as suppliers.

The full analysis is free to read with a work email on this page.

Source: Dawaa News MENA

Latest deals

All GCC deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →